Group 1 - The stock market has shown resilience by rallying to new highs despite previous concerns over tariffs [1] - Gary Alexander has extensive experience in technology sectors, both on Wall Street and in Silicon Valley, influencing his insights into current industry trends [1] - Alexander has been a contributor to Seeking Alpha since 2017, indicating a long-standing engagement with investment analysis [1] Group 2 - The article does not provide specific financial data or performance metrics related to any companies or sectors [2][3]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of SelectQuote, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Allegations and Impact - SelectQuote has been charged by the U.S. Department of Justice for allegedly paying illegal kickbacks to brokers from 2016 to 2021, which resulted in a significant stock price drop of 19.2% on May 1, 2025 [3]. - The investigation by Rosen Law Firm is a response to these allegations, indicating potential legal repercussions for SelectQuote and its shareholders [1][2]. Group 2: Class Action Information - Shareholders who purchased SelectQuote securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements including over $438 million secured in 2019 alone [4].

Core Viewpoint - SelectQuote (SLQT) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. SelectQuote's Earnings Outlook - The recent upgrade for SelectQuote reflects an improvement in its underlying business, driven by rising earnings estimates, which is expected to create buying pressure and increase its stock price [5][10]. - Over the past three months, the Zacks Consensus Estimate for SelectQuote has increased by 33.3%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with a proven track record of generating significant returns, particularly for Zacks Rank 1 stocks [7]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, positioning SelectQuote favorably for potential market-beating returns [9][10].

Company Overview - SelectQuote, Inc. (SLQT) operates as a technology-enabled, direct-to-consumer platform that connects U.S. consumers with various insurance products across senior health, life, auto, and home markets [1] Research Approach - Moretus Research provides high-quality equity research focused on U.S. public markets, utilizing a structured framework to identify companies with durable business models and mispriced cash flow potential [1] - The research emphasizes rigorous fundamental analysis combined with a judgment-driven process, avoiding noise and overly complex forecasting [1] - Valuation methods are based on sector-relevant multiples tailored to each company's business model and capital structure, prioritizing comparability and simplicity [1] Investment Focus - Moretus Research tends to favor underappreciated companies undergoing structural changes or temporary dislocations, where dispassionate analysis can lead to asymmetric returns [1] - The research reflects a commitment to capital discipline and long-term compounding, aiming to elevate the standard for independent investment research [1]

Core Viewpoint - SelectQuote Inc. is facing significant investor pressure due to disappointing quarterly results and ongoing legal issues, leading to a substantial decline in its stock price [1][3]. Financial Performance - For the quarter ended March 2025, SelectQuote reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share [2]. - The company posted revenues of $408.16 million, falling short of the Zacks Consensus Estimate of $417.01 million by 2.12% [2]. Legal Issues - The U.S. Department of Justice (DOJ) announced a lawsuit against SelectQuote and several major health insurers on May 1, 2025, alleging violations of the False Claims Act related to the marketing of Medicare Advantage plans [3][4]. - The lawsuit claims that from 2016 to at least 2021, SelectQuote and other brokers were incentivized to steer beneficiaries toward high-commission plans, potentially disregarding the suitability of those plans [4]. Investor Sentiment - The combination of a weaker-than-expected earnings report and serious legal allegations has heightened concerns regarding SelectQuote's financial stability and operational integrity [5]. - Hagens Berman is investigating potential violations of U.S. securities laws and is encouraging investors who suffered losses to come forward [2][5].

Company Overview - SelectQuote is a direct-to-consumer insurance platform that offers health, life, auto, and home insurance policies, as well as medication management services through its SelectRx pharmacy division [3] Allegations and Legal Issues - The Department of Justice filed a False Claims Act complaint against SelectQuote on May 1, 2025, alleging the company received millions of dollars in kickbacks from Humana in exchange for specific Medicare Advantage plan enrollments [4] - The complaint claims SelectQuote maintained a sales division that exclusively offered Humana policies and directed a significant portion of its business to Humana [4] Market Reaction - Following the filing of the complaint, SelectQuote's stock price fell by $0.61 per share, or 19.2%, closing at $2.56 per share on May 1, 2025 [5]

Core Viewpoint - SelectQuote Inc. is facing significant investor pressure due to a sharp decline in share prices following disappointing quarterly earnings and ongoing legal issues related to alleged violations of the False Claims Act [1][3]. Financial Performance - For the quarter ended March 2025, SelectQuote reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share [2]. - The company posted revenues of $408.16 million, falling short of the Zacks Consensus Estimate of $417.01 million by 2.12% [2]. Legal Issues - The U.S. Department of Justice (DOJ) announced a lawsuit on May 1, 2025, alleging that SelectQuote and other health insurers violated the False Claims Act in their marketing of Medicare Advantage plans [3][4]. - The lawsuit claims that from 2016 to at least 2021, SelectQuote received significant payments from insurers for Medicare Advantage enrollments, but allegedly steered beneficiaries toward higher-commission plans, disregarding their suitability [4]. Investor Sentiment - The combination of poor earnings and serious legal allegations has heightened concerns regarding SelectQuote's financial stability and operational integrity [5]. - Hagens Berman, a law firm investigating SelectQuote, emphasizes that the recent earnings figures raise existing concerns about the company's alleged steering tactics in light of the DOJ's allegations [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of SelectQuote, Inc. due to allegations of materially misleading business information issued by the company [1] Group 1: Legal Actions and Investigations - SelectQuote is facing a class action lawsuit initiated by Rosen Law Firm, which seeks recovery of investor losses without any out-of-pocket fees for the shareholders [2] - The U.S. Department of Justice has charged SelectQuote in connection with a False Claims Act complaint against three national health insurance companies and three brokers, alleging unlawful kickbacks and discrimination against disabled Americans [3] - The allegations state that from 2016 to at least 2021, SelectQuote's associated insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments into Medicare Advantage plans [3] Group 2: Market Impact - Following the announcement of the charges on May 1, 2025, SelectQuote's stock experienced a significant decline of 19.2% [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 [4] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving SelectQuote, Inc. and its officers or directors [1] Group 1: Legal Issues - The U.S. Department of Justice filed a False Claims Act complaint against SelectQuote and other health insurance companies, alleging that from 2016 to 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [3] - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.24%, closing at $2.56 per share on May 1, 2025 [3] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of SelectQuote, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Investigation and Class Action - Shareholders who purchased SelectQuote securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to SelectQuote [2]. Group 2: Allegations and Stock Impact - SelectQuote was charged by the U.S. Department of Justice for allegedly paying hundreds of millions of dollars in illegal kickbacks to brokers from 2016 to 2021 in exchange for enrollments into Medicare Advantage plans [3]. - Following the announcement of these charges, SelectQuote's stock experienced a significant decline of 19.2% on May 1, 2025 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].